Evommune, the decline loses steam
Evommune: the Sell signal is in its 8th week, but strength is near zero
Our view last week
Evommune stock technical analysis: the Sell signal has been running for 6 weeks, but the last two have flipped the script. After a sharp drop in late July, the stock jumped 25% and then another 4%, with buyers above 90% of volume in both weeks. The weekly picture has turned bullish, even as a distribution warning stays lit underneath; for anyone short, the trade is back in the red, past a 13% loss.
This week's summary
Evommune stock technical analysis: the Sell signal turns 8 weeks old, but the bearish push has nearly run out of steam. Signal Strength has dropped to 4 out of 100, and price clawed back ground over the last two weeks before slipping again. The picture stays in tension: IQS at 72 out of 100, elevated volatility, and trading our model still advises against.
IQS Phase
72
in tension
Signal Strength
4
decline fading out
Sizing
MINIMUM
Ranking
#77 / 93
US stocks
Trade P&L %
-8.18%
from signal to date, no stop loss
Rank position
ranks 77th among the 93 sell signals for US stocks in our ranking, with a signal strength of 4 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein strong phase
Performanceweekly +4.33% · monthly +9.53%
EVMN belongs to the health care sector (reference ETF XLV). The sector is classified in strong phase according to our weekly reading.
restricted Platinum content